You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMirabegron
Accession NumberDB08893
TypeSmall Molecule
GroupsApproved
DescriptionMirabegron is a beta-3 adrenergic receptor agonist for the management of overactive bladder. It is an alternative to antimuscarinic drugs for this indication. FDA approved on June 28, 2012.
Structure
Thumb
Synonyms
Myrbetriq
External Identifiers
  • YM-178
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release25 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
BetmigaTablet, extended release50 mgOralAstellas Pharma Europe B.V.2012-12-20Not applicableEu
MyrbetriqTablet, film coated, extended release50 mg/1OralAstellas Pharma US, Inc.2012-06-28Not applicableUs
MyrbetriqTablet, extended release25 mgOralAstellas Pharma Canada Inc2013-03-28Not applicableCanada
MyrbetriqTablet, extended release50 mgOralAstellas Pharma Canada Inc2013-03-28Not applicableCanada
MyrbetriqTablet, film coated, extended release25 mg/1OralAvera Mc Kennan Hospital2015-03-23Not applicableUs
MyrbetriqTablet, film coated, extended release25 mg/1OralAstellas Pharma US, Inc.2012-06-28Not applicableUs
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
BetanisNot Available
Metmiga Not Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNIIMVR3JL3B2V
CAS number223673-61-8
WeightAverage: 396.506
Monoisotopic: 396.161996722
Chemical FormulaC21H24N4O2S
InChI KeyPBAPPPCECJKMCM-IBGZPJMESA-N
InChI
InChI=1S/C21H24N4O2S/c22-21-25-18(14-28-21)12-20(27)24-17-8-6-15(7-9-17)10-11-23-13-19(26)16-4-2-1-3-5-16/h1-9,14,19,23,26H,10-13H2,(H2,22,25)(H,24,27)/t19-/m0/s1
IUPAC Name
2-(2-amino-1,3-thiazol-4-yl)-N-[4-(2-{[(2R)-2-hydroxy-2-phenylethyl]amino}ethyl)phenyl]acetamide
SMILES
NC1=NC(CC(=O)NC2=CC=C(CCNC[[email protected]](O)C3=CC=CC=C3)C=C2)=CS1
Pharmacology
IndicationMirabegron is a beta-3 adrenergic agonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Structured Indications
PharmacodynamicsMirabegron has little effect on the mean maximum flow rate or mean detrusor pressure at maximum flow rate in patients with lower urinary tract symptoms and bladder outlet obstruction. Furthermore, mirabegron increases blood pressure in a dose dependent manner. However, this effect is reversible when mirabegron is discontinued. Mirabegron also increases heart rate in a dose dependent manner. The dose in which half-maximal efficacy is demonstrated is 25 mg. Comparatively, the dose in which maximal efficacy is demonstrated is 100 mg.
Mechanism of actionMirabegron is a potent and selective agonist for beta-3 adrenergic receptors. Once beta-3 receptors are activated, the detrusor smooth muscle relaxes to allow for a larger bladder capacity. At higher doses (200 mg), there is a potential for mirabegron to activate beta-1 and beta-2 adrenergic receptors.
TargetKindPharmacological actionActionsOrganismUniProt ID
Beta-3 adrenergic receptorProteinyes
agonist
HumanP13945 details
Related Articles
AbsorptionThe absolute bioavailability increases from 29% at a dose of 25 mg to 35% at a dose of 50 mg. Mean Cmax and AUC increase more than dose proportionally. This relationship is more apparent at doses above 50 mg. Females generally have a lower magnitude of increase of Cmax and AUCtau compared to males when doses of mirabegron doubles or quadruples. Steady state concentrations are achieved within 7 days of once daily dosing with mirabegron. After once daily administration, plasma exposure of mirabegron at steady state is approximately double that seen after a single dose. Tmax, oral dose, healthy subjects= 3.5 hours;
Volume of distribution

Vd, steady state, IV dose = 1670 L. This high value suggests that mirabegron is extensively distributed in the body.

Protein binding71% bound to plasma proteins. It binds to albumin and alpha-1-acid glycoprotein with moderate affinity.
Metabolism

Mirabegron is metabolized via multiple pathways involving dealkylation, oxidation, (direct) glucuronidation, and amide hydrolysis. The major circulating entity is mirabegron. Two major and inactive metabolites (phase 2 glucuronides) are produced. Although mirabegron is a substrate for CYP2D6 and CYP3A4, its role in the elimination of the drug is limited. Studies also suggest that CYP3A4 is the main enzyme that facilitates the oxidative metabolism of the drug. Furthermore, butylcholinesterase, uridine diphospho-glucuronosyltransferases (UGT), and possibly alcohol dehydrogenase may be involved with the metabolism of mirabegron.

Route of eliminationMirabegron is eliminated via urine (radiolabeled drug: 55%; unchanged drug: ~25%) and feces (radiolabeled drug: 34%; unchanged drug: 0%). Renal elimination of mirabegron is primarily through active tubular secretion and glomerular filtration. Extent of elimination via urine is dose-dependent.
Half lifeTerminal elimination half-life = 50 hours
Clearance

Total body clearance (CLtot), IV dose = 57 L/h;
Renal clearance (CLR) = 13 L/h

ToxicityMost commonly reported adverse reactions (> 2% and > placebo) were hypertension, nasopharyngitis, urinary tract infection and headache
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Mirabegron.Experimental, Illicit
AbirateroneThe serum concentration of Mirabegron can be increased when it is combined with Abiraterone.Approved
AcetaminophenThe serum concentration of Mirabegron can be increased when it is combined with Acetaminophen.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Mirabegron.Approved
AclidiniumThe risk or severity of adverse effects can be increased when Aclidinium is combined with Mirabegron.Approved
AfatinibThe serum concentration of Mirabegron can be increased when it is combined with Afatinib.Approved
AjmalineThe metabolism of Ajmaline can be decreased when combined with Mirabegron.Approved
AlbendazoleThe serum concentration of Mirabegron can be increased when it is combined with Albendazole.Approved, Vet Approved
AldosteroneThe serum concentration of Mirabegron can be decreased when it is combined with Aldosterone.Experimental
AlectinibThe serum concentration of Mirabegron can be increased when it is combined with Alectinib.Approved
AlfentanilThe serum concentration of Mirabegron can be increased when it is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may decrease the vasoconstricting activities of Mirabegron.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Mirabegron.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Mirabegron.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Mirabegron.Approved, Withdrawn
AmantadineThe serum concentration of Mirabegron can be increased when it is combined with Amantadine.Approved
Aminohippuric acidThe serum concentration of Mirabegron can be increased when it is combined with Aminohippuric acid.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Mirabegron.Approved, Withdrawn
AmiodaroneThe metabolism of Mirabegron can be decreased when combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Mirabegron can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Mirabegron can be increased when it is combined with Amlodipine.Approved
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Mirabegron.Approved
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Mirabegron.Approved, Illicit
AmprenavirThe serum concentration of Mirabegron can be decreased when it is combined with Amprenavir.Approved
AmsacrineThe serum concentration of Mirabegron can be increased when it is combined with Amsacrine.Approved
AnagrelideMirabegron may increase the QTc-prolonging activities of Anagrelide.Approved
Anisotropine MethylbromideThe risk or severity of adverse effects can be increased when Anisotropine Methylbromide is combined with Mirabegron.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Mirabegron.Approved
AprepitantThe serum concentration of Mirabegron can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Mirabegron.Approved
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Mirabegron.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Mirabegron.Approved, Investigational
Arsenic trioxideMirabegron may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherMirabegron may increase the QTc-prolonging activities of Artemether.Approved
AsenapineMirabegron may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe serum concentration of Mirabegron can be increased when it is combined with Astemizole.Approved, Withdrawn
AtazanavirThe metabolism of Mirabegron can be decreased when combined with Atazanavir.Approved, Investigational
AtenololThe serum concentration of Mirabegron can be increased when it is combined with Atenolol.Approved
AtomoxetineThe metabolism of Mirabegron can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Mirabegron can be increased when it is combined with Atorvastatin.Approved
Atracurium besylateThe risk or severity of adverse effects can be increased when Atracurium besylate is combined with Mirabegron.Approved
AtropineThe risk or severity of adverse effects can be increased when Atropine is combined with Mirabegron.Approved, Vet Approved
AzelastineThe serum concentration of Mirabegron can be increased when it is combined with Azelastine.Approved
AzithromycinMirabegron may increase the QTc-prolonging activities of Azithromycin.Approved
BedaquilineMirabegron may increase the QTc-prolonging activities of Bedaquiline.Approved
BenactyzineThe risk or severity of adverse effects can be increased when Benactyzine is combined with Mirabegron.Withdrawn
BenzatropineThe risk or severity of adverse effects can be increased when Benzatropine is combined with Mirabegron.Approved
BenzocaineThe serum concentration of Mirabegron can be increased when it is combined with Benzocaine.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Mirabegron.Approved
Benzylpenicilloyl PolylysineMirabegron may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.Approved
BepridilThe serum concentration of Mirabegron can be increased when it is combined with Bepridil.Approved, Withdrawn
BetaxololThe metabolism of Mirabegron can be decreased when combined with Betaxolol.Approved
BexaroteneThe serum concentration of Mirabegron can be decreased when it is combined with Bexarotene.Approved, Investigational
BiperidenThe risk or severity of adverse effects can be increased when Biperiden is combined with Mirabegron.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Mirabegron.Approved
BoceprevirThe metabolism of Mirabegron can be decreased when combined with Boceprevir.Approved
BortezomibThe metabolism of Mirabegron can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Mirabegron can be decreased when it is combined with Bosentan.Approved, Investigational
BosutinibThe serum concentration of Mirabegron can be increased when it is combined with Bosutinib.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Mirabegron.Approved
BromocriptineBromocriptine may increase the hypertensive activities of Mirabegron.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Mirabegron.Approved
BucindololBucindolol may decrease the vasoconstricting activities of Mirabegron.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Mirabegron.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Mirabegron.Approved, Investigational
BuprenorphineThe serum concentration of Mirabegron can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Mirabegron can be decreased when combined with Bupropion.Approved
BuspironeThe serum concentration of Mirabegron can be increased when it is combined with Buspirone.Approved, Investigational
CabazitaxelThe serum concentration of Mirabegron can be increased when it is combined with Cabazitaxel.Approved
CabergolineCabergoline may increase the hypertensive activities of Mirabegron.Approved
CaffeineThe serum concentration of Mirabegron can be increased when it is combined with Caffeine.Approved
CanagliflozinThe serum concentration of Mirabegron can be increased when it is combined with Canagliflozin.Approved
CandesartanThe serum concentration of Mirabegron can be increased when it is combined with Candesartan.Approved
CaptoprilThe serum concentration of Mirabegron can be increased when it is combined with Captopril.Approved
CarbamazepineThe metabolism of Mirabegron can be increased when combined with Carbamazepine.Approved, Investigational
CariprazineThe metabolism of Cariprazine can be decreased when combined with Mirabegron.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Mirabegron.Approved
CarvedilolThe serum concentration of Mirabegron can be increased when it is combined with Carvedilol.Approved, Investigational
CaspofunginThe serum concentration of Mirabegron can be increased when it is combined with Caspofungin.Approved
CelecoxibThe metabolism of Mirabegron can be decreased when combined with Celecoxib.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Mirabegron.Approved, Vet Approved
CeritinibThe serum concentration of Mirabegron can be increased when it is combined with Ceritinib.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Mirabegron.Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Mirabegron.Approved, Illicit
ChloroquineMirabegron may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Mirabegron.Approved
ChlorphenoxamineThe risk or severity of adverse effects can be increased when Chlorphenoxamine is combined with Mirabegron.Withdrawn
ChlorpromazineMirabegron may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorpropamideThe serum concentration of Mirabegron can be increased when it is combined with Chlorpropamide.Approved
ChlorprothixeneThe serum concentration of Mirabegron can be increased when it is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Mirabegron.Approved
CholecalciferolThe metabolism of Mirabegron can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CholesterolThe serum concentration of Mirabegron can be increased when it is combined with Cholesterol.Experimental
Cholic AcidThe serum concentration of Mirabegron can be decreased when it is combined with Cholic Acid.Approved
CilazaprilThe serum concentration of Mirabegron can be increased when it is combined with Cilazapril.Approved
CilostazolThe metabolism of Cilostazol can be decreased when combined with Mirabegron.Approved
CimetidineThe serum concentration of Mirabegron can be decreased when it is combined with Cimetidine.Approved
CinacalcetThe metabolism of Mirabegron can be decreased when combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Mirabegron.Approved
CiprofloxacinMirabegron may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideMirabegron may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramMirabegron may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinThe metabolism of Mirabegron can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Mirabegron can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Mirabegron.Approved
ClobazamThe metabolism of Mirabegron can be decreased when combined with Clobazam.Approved, Illicit
ClofazimineThe serum concentration of Mirabegron can be increased when it is combined with Clofazimine.Approved, Investigational
ClomipramineThe serum concentration of Mirabegron can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineThe metabolism of Clonidine can be decreased when combined with Mirabegron.Approved
ClotrimazoleThe metabolism of Mirabegron can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineMirabegron may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Mirabegron can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Mirabegron can be decreased when combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Mirabegron.Approved, Illicit
ColchicineThe serum concentration of Mirabegron can be increased when it is combined with Colchicine.Approved
ColforsinThe serum concentration of Mirabegron can be increased when it is combined with Colforsin.Experimental
ConivaptanThe serum concentration of Mirabegron can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibMirabegron may increase the QTc-prolonging activities of Crizotinib.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Mirabegron.Approved
CyclopentolateThe risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mirabegron.Approved
CyclophosphamideThe serum concentration of Mirabegron can be increased when it is combined with Cyclophosphamide.Approved, Investigational
CyclosporineThe metabolism of Mirabegron can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Mirabegron can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Mirabegron can be increased when it is combined with Daclatasvir.Approved
DactinomycinThe serum concentration of Mirabegron can be increased when it is combined with Dactinomycin.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Mirabegron.Approved
DarifenacinThe risk or severity of adverse effects can be increased when Darifenacin is combined with Mirabegron.Approved, Investigational
DarunavirThe serum concentration of Mirabegron can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Mirabegron.Approved
DasatinibThe serum concentration of Mirabegron can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Mirabegron can be decreased when it is combined with Daunorubicin.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Mirabegron.Approved
DeferasiroxThe serum concentration of Mirabegron can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Mirabegron can be decreased when combined with Delavirdine.Approved
DesipramineThe serum concentration of Desipramine can be increased when it is combined with Mirabegron.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Mirabegron.Approved, Investigational
DesvenlafaxineDesvenlafaxine may increase the tachycardic activities of Mirabegron.Approved
DexamethasoneThe serum concentration of Mirabegron can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexetimideThe risk or severity of adverse effects can be increased when Dexetimide is combined with Mirabegron.Withdrawn
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Mirabegron.Approved, Illicit, Withdrawn
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Mirabegron.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Mirabegron.Approved, Illicit
DextromethorphanThe serum concentration of Mirabegron can be increased when it is combined with Dextromethorphan.Approved
DiclofenacThe serum concentration of Mirabegron can be increased when it is combined with Diclofenac.Approved, Vet Approved
DicyclomineThe risk or severity of adverse effects can be increased when Dicyclomine is combined with Mirabegron.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Mirabegron.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Mirabegron.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the hypertensive activities of Mirabegron.Approved
DiltiazemThe metabolism of Mirabegron can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Mirabegron can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe serum concentration of Mirabegron can be increased when it is combined with Dipyridamole.Approved
DisopyramideMirabegron may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideMirabegron may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronMirabegron may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneMirabegron may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Mirabegron.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Mirabegron.Approved
DoxazosinThe serum concentration of Mirabegron can be increased when it is combined with Doxazosin.Approved
DoxepinThe serum concentration of Mirabegron can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Mirabegron.Approved, Investigational
DoxorubicinThe serum concentration of Mirabegron can be decreased when it is combined with Doxorubicin.Approved, Investigational
DoxycyclineThe metabolism of Mirabegron can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronabinolThe serum concentration of Mirabegron can be increased when it is combined with Dronabinol.Approved, Illicit
DronedaroneMirabegron may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolMirabegron may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineDuloxetine may increase the tachycardic activities of Mirabegron.Approved
EfavirenzThe serum concentration of Mirabegron can be decreased when it is combined with Efavirenz.Approved, Investigational
ElbasvirThe serum concentration of Mirabegron can be increased when it is combined with Elbasvir.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Mirabegron.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Mirabegron.Approved
EnalaprilThe serum concentration of Mirabegron can be increased when it is combined with Enalapril.Approved, Vet Approved
EncainideThe metabolism of Encainide can be decreased when combined with Mirabegron.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Mirabegron.Investigational
EnzalutamideThe serum concentration of Mirabegron can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Mirabegron.Approved, Investigational
Ergoloid mesylateErgoloid mesylate may increase the hypertensive activities of Mirabegron.Approved
ErgonovineErgonovine may increase the hypertensive activities of Mirabegron.Approved
ErgotamineErgotamine may increase the hypertensive activities of Mirabegron.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Mirabegron.Approved, Investigational
ErythromycinMirabegron may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramMirabegron may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Mirabegron can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Mirabegron.Investigational
EstramustineThe serum concentration of Mirabegron can be increased when it is combined with Estramustine.Approved
EstriolThe serum concentration of Mirabegron can be decreased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Mirabegron can be decreased when it is combined with Estrone.Approved
EthopropazineThe risk or severity of adverse effects can be increased when Ethopropazine is combined with Mirabegron.Approved
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Mirabegron.Approved, Illicit
EtoposideThe serum concentration of Mirabegron can be increased when it is combined with Etoposide.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Mirabegron.Approved, Investigational
EtravirineThe serum concentration of Mirabegron can be decreased when it is combined with Etravirine.Approved
FelodipineThe serum concentration of Mirabegron can be increased when it is combined with Felodipine.Approved, Investigational
FentanylThe serum concentration of Mirabegron can be increased when it is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Mirabegron.Approved
FexofenadineThe serum concentration of Mirabegron can be increased when it is combined with Fexofenadine.Approved
FidaxomicinThe serum concentration of Mirabegron can be increased when it is combined with Fidaxomicin.Approved
FingolimodThe metabolism of Fingolimod can be decreased when combined with Mirabegron.Approved, Investigational
FlecainideThe serum concentration of Flecainide can be increased when it is combined with Mirabegron.Approved, Withdrawn
FluconazoleThe metabolism of Mirabegron can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Mirabegron.Approved
FluoxetineMirabegron may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolMirabegron may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe serum concentration of Mirabegron can be increased when it is combined with Fluphenazine.Approved
FlurazepamThe serum concentration of Mirabegron can be increased when it is combined with Flurazepam.Approved, Illicit
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Mirabegron.Approved
FluvoxamineThe metabolism of Mirabegron can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Mirabegron.Approved, Investigational
FosamprenavirThe metabolism of Mirabegron can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Mirabegron can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Mirabegron can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Mirabegron can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidMirabegron may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineThe metabolism of Galantamine can be decreased when combined with Mirabegron.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Gallamine Triethiodide is combined with Mirabegron.Approved
GefitinibThe serum concentration of Mirabegron can be increased when it is combined with Gefitinib.Approved, Investigational
GemifloxacinMirabegron may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Mirabegron can be increased when it is combined with Genistein.Investigational
GlyburideThe serum concentration of Mirabegron can be increased when it is combined with Glyburide.Approved
GlycerolThe serum concentration of Mirabegron can be increased when it is combined with Glycerol.Experimental
GlycopyrroniumThe risk or severity of adverse effects can be increased when Glycopyrronium is combined with Mirabegron.Approved, Investigational, Vet Approved
GoserelinMirabegron may increase the QTc-prolonging activities of Goserelin.Approved
Gramicidin DThe serum concentration of Mirabegron can be increased when it is combined with Gramicidin D.Approved
GranisetronMirabegron may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GrepafloxacinThe serum concentration of Mirabegron can be increased when it is combined with Grepafloxacin.Withdrawn
HalofantrineThe metabolism of Halofantrine can be decreased when combined with Mirabegron.Approved
HaloperidolMirabegron may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Mirabegron.Approved, Vet Approved
HexamethoniumThe risk or severity of adverse effects can be increased when Hexamethonium is combined with Mirabegron.Experimental
HomatropineThe risk or severity of adverse effects can be increased when Homatropine is combined with Mirabegron.Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Mirabegron.Approved, Illicit
HydrocortisoneThe serum concentration of Mirabegron can be increased when it is combined with Hydrocortisone.Approved, Vet Approved
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Mirabegron.Approved, Illicit
HyoscyamineThe risk or severity of adverse effects can be increased when Hyoscyamine is combined with Mirabegron.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Mirabegron.Approved
IbutilideMirabegron may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Mirabegron.Approved
IdelalisibThe serum concentration of Mirabegron can be increased when it is combined with Idelalisib.Approved
IloperidoneMirabegron may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Mirabegron can be decreased when combined with Imatinib.Approved
ImipramineThe serum concentration of Mirabegron can be increased when it is combined with Imipramine.Approved
IndinavirThe metabolism of Mirabegron can be decreased when combined with Indinavir.Approved
IndomethacinThe serum concentration of Mirabegron can be increased when it is combined with Indomethacin.Approved, Investigational
IndoraminIndoramin may decrease the vasoconstricting activities of Mirabegron.Withdrawn
Ipratropium bromideThe risk or severity of adverse effects can be increased when Ipratropium bromide is combined with Mirabegron.Approved
IsavuconazoniumThe metabolism of Mirabegron can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Mirabegron can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Mirabegron can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Mirabegron can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Mirabegron can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Mirabegron can be increased when it is combined with Ivermectin.Approved, Vet Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Mirabegron.Approved
KetamineThe serum concentration of Mirabegron can be increased when it is combined with Ketamine.Approved, Vet Approved
KetoconazoleThe metabolism of Mirabegron can be decreased when combined with Ketoconazole.Approved, Investigational
KetoconazoleThe serum concentration of Mirabegron can be increased when it is combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Mirabegron.Approved
LansoprazoleThe serum concentration of Mirabegron can be increased when it is combined with Lansoprazole.Approved, Investigational
LapatinibThe serum concentration of Mirabegron can be increased when it is combined with Lapatinib.Approved, Investigational
LenvatinibMirabegron may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideMirabegron may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevodopaThe metabolism of Levodopa can be decreased when combined with Mirabegron.Approved
LevofloxacinMirabegron may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranLevomilnacipran may increase the tachycardic activities of Mirabegron.Approved
LevothyroxineThe serum concentration of Mirabegron can be decreased when it is combined with Levothyroxine.Approved
LidocaineThe serum concentration of Mirabegron can be increased when it is combined with Lidocaine.Approved, Vet Approved
LiothyronineThe serum concentration of Mirabegron can be decreased when it is combined with Liothyronine.Approved, Vet Approved
LiotrixThe serum concentration of Mirabegron can be decreased when it is combined with Liotrix.Approved
LisinoprilThe serum concentration of Mirabegron can be increased when it is combined with Lisinopril.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Mirabegron.Approved
LomitapideThe serum concentration of Mirabegron can be increased when it is combined with Lomitapide.Approved
LomustineThe metabolism of Lomustine can be decreased when combined with Mirabegron.Approved
LoperamideThe serum concentration of Mirabegron can be increased when it is combined with Loperamide.Approved
LopinavirThe metabolism of Mirabegron can be decreased when combined with Lopinavir.Approved
LoratadineThe serum concentration of Mirabegron can be increased when it is combined with Loratadine.Approved
LorcaserinThe metabolism of Mirabegron can be decreased when combined with Lorcaserin.Approved
LosartanThe serum concentration of Mirabegron can be increased when it is combined with Losartan.Approved
LovastatinThe metabolism of Mirabegron can be decreased when combined with Lovastatin.Approved, Investigational
LuliconazoleThe serum concentration of Mirabegron can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Mirabegron can be decreased when it is combined with Lumacaftor.Approved
LumefantrineMirabegron may increase the QTc-prolonging activities of Lumefantrine.Approved
MaprotilineThe serum concentration of Mirabegron can be increased when it is combined with Maprotiline.Approved
MebendazoleThe serum concentration of Mirabegron can be increased when it is combined with Mebendazole.Approved, Vet Approved
MecamylamineThe risk or severity of adverse effects can be increased when Mecamylamine is combined with Mirabegron.Approved
MefloquineThe serum concentration of Mirabegron can be increased when it is combined with Mefloquine.Approved
Megestrol acetateThe serum concentration of Mirabegron can be increased when it is combined with Megestrol acetate.Approved, Vet Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Mirabegron.Investigational, Withdrawn
MeprobamateThe serum concentration of Mirabegron can be increased when it is combined with Meprobamate.Approved, Illicit
MequitazineThe metabolism of Mequitazine can be decreased when combined with Mirabegron.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Mirabegron.Approved
MethadoneMirabegron may increase the QTc-prolonging activities of Methadone.Approved
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Mirabegron.Approved, Illicit
MethanthelineThe risk or severity of adverse effects can be increased when Methantheline is combined with Mirabegron.Approved
MethotrimeprazineThe metabolism of Mirabegron can be decreased when combined with Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Mirabegron.Approved, Vet Approved
MethylphenidateThe metabolism of Methylphenidate can be decreased when combined with Mirabegron.Approved, Investigational
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Mirabegron.Approved, Illicit, Withdrawn
MetixeneThe risk or severity of adverse effects can be increased when Metixene is combined with Mirabegron.Approved
MetoclopramideThe metabolism of Metoclopramide can be decreased when combined with Mirabegron.Approved, Investigational
MetoprololMirabegron may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MexiletineThe metabolism of Mexiletine can be decreased when combined with Mirabegron.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Mirabegron.Approved
MibefradilThe serum concentration of Mirabegron can be increased when it is combined with Mibefradil.Withdrawn
MiconazoleThe serum concentration of Mirabegron can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Mirabegron can be decreased when it is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Mirabegron.Approved, Investigational
MilnacipranMilnacipran may increase the tachycardic activities of Mirabegron.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Mirabegron.Approved
MirtazapineThe metabolism of Mirtazapine can be decreased when combined with Mirabegron.Approved
MitomycinThe serum concentration of Mirabegron can be increased when it is combined with Mitomycin.Approved
MitotaneThe serum concentration of Mirabegron can be decreased when it is combined with Mitotane.Approved
MitoxantroneThe serum concentration of Mirabegron can be decreased when it is combined with Mitoxantrone.Approved, Investigational
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Mirabegron.Approved
ModafinilThe serum concentration of Mirabegron can be decreased when it is combined with Modafinil.Approved, Investigational
MorphineThe serum concentration of Mirabegron can be increased when it is combined with Morphine.Approved, Investigational
MoxifloxacinMirabegron may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
N-butylscopolammonium bromideThe risk or severity of adverse effects can be increased when N-butylscopolammonium bromide is combined with Mirabegron.Vet Approved
NafcillinThe serum concentration of Mirabegron can be decreased when it is combined with Nafcillin.Approved
NaltrexoneThe serum concentration of Mirabegron can be increased when it is combined with Naltrexone.Approved, Investigational, Vet Approved
NaringeninThe serum concentration of Mirabegron can be increased when it is combined with Naringenin.Experimental
NateglinideThe metabolism of Nateglinide can be decreased when combined with Mirabegron.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Mirabegron.Approved, Investigational
NefazodoneThe metabolism of Mirabegron can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Mirabegron can be decreased when combined with Nelfinavir.Approved
NeostigmineThe serum concentration of Mirabegron can be increased when it is combined with Neostigmine.Approved, Vet Approved
NetupitantThe serum concentration of Mirabegron can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Mirabegron can be increased when combined with Nevirapine.Approved
NicardipineThe serum concentration of Mirabegron can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Mirabegron.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Mirabegron.Approved
NifedipineThe serum concentration of Mirabegron can be decreased when it is combined with Nifedipine.Approved
NilotinibMirabegron may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NisoldipineThe serum concentration of Mirabegron can be increased when it is combined with Nisoldipine.Approved
NitrazepamThe serum concentration of Mirabegron can be increased when it is combined with Nitrazepam.Approved
NitrendipineThe serum concentration of Mirabegron can be increased when it is combined with Nitrendipine.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Mirabegron.Approved, Vet Approved
NorethisteroneThe serum concentration of Mirabegron can be decreased when it is combined with Norethisterone.Approved
NortriptylineThe metabolism of Nortriptyline can be decreased when combined with Mirabegron.Approved
NVA237The risk or severity of adverse effects can be increased when NVA237 is combined with Mirabegron.Investigational
OfloxacinMirabegron may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineThe metabolism of Olanzapine can be decreased when combined with Mirabegron.Approved, Investigational
OlaparibThe metabolism of Mirabegron can be decreased when combined with Olaparib.Approved
OmeprazoleThe serum concentration of Mirabegron can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronMirabegron may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Mirabegron.Approved
OsimertinibThe serum concentration of Mirabegron can be increased when it is combined with Osimertinib.Approved
OxybutyninThe risk or severity of adverse effects can be increased when Oxybutynin is combined with Mirabegron.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Mirabegron.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
OxyphenoniumThe risk or severity of adverse effects can be increased when Oxyphenonium is combined with Mirabegron.Approved
P-NitrophenolThe serum concentration of Mirabegron can be increased when it is combined with P-Nitrophenol.Experimental
PaclitaxelThe serum concentration of Mirabegron can be increased when it is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe serum concentration of Mirabegron can be increased when it is combined with Palbociclib.Approved
PaliperidoneMirabegron may increase the QTc-prolonging activities of Paliperidone.Approved
Palmitic AcidThe serum concentration of Mirabegron can be increased when it is combined with Palmitic Acid.Experimental
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Mirabegron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when Pancuronium is combined with Mirabegron.Approved
PanobinostatThe serum concentration of Mirabegron can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe serum concentration of Mirabegron can be increased when it is combined with Pantoprazole.Approved
ParoxetineThe metabolism of Mirabegron can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibMirabegron may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Mirabegron can be decreased when it is combined with Peginterferon alfa-2b.Approved
PentamidineMirabegron may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Mirabegron can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe risk or severity of adverse effects can be increased when Pentolinium is combined with Mirabegron.Approved
PerflutrenMirabegron may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Mirabegron.Approved
PerindoprilThe serum concentration of Mirabegron can be increased when it is combined with Perindopril.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Mirabegron.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Mirabegron.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Mirabegron.Withdrawn
PhenforminThe metabolism of Phenformin can be decreased when combined with Mirabegron.Approved, Withdrawn
PhenobarbitalThe metabolism of Mirabegron can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Mirabegron can be increased when combined with Phenytoin.Approved, Vet Approved
PimozideMirabegron may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Mirabegron.Approved
PipecuroniumThe risk or severity of adverse effects can be increased when Pipecuronium is combined with Mirabegron.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Mirabegron.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Mirabegron.Approved
PirenzepineThe risk or severity of adverse effects can be increased when Pirenzepine is combined with Mirabegron.Approved
Platelet Activating FactorThe serum concentration of Mirabegron can be decreased when it is combined with Platelet Activating Factor.Experimental
PonatinibThe serum concentration of Mirabegron can be increased when it is combined with Ponatinib.Approved
PosaconazoleThe metabolism of Mirabegron can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PravastatinThe serum concentration of Mirabegron can be increased when it is combined with Pravastatin.Approved
PrazosinThe serum concentration of Mirabegron can be increased when it is combined with Prazosin.Approved
PrednisoneThe serum concentration of Mirabegron can be increased when it is combined with Prednisone.Approved, Vet Approved
PrimaquineMirabegron may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Mirabegron can be increased when combined with Primidone.Approved, Vet Approved
ProbenecidThe serum concentration of Mirabegron can be increased when it is combined with Probenecid.Approved
ProcainamideMirabegron may increase the QTc-prolonging activities of Procainamide.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Mirabegron.Approved, Vet Approved
ProcyclidineThe risk or severity of adverse effects can be increased when Procyclidine is combined with Mirabegron.Approved
ProgesteroneThe serum concentration of Mirabegron can be decreased when it is combined with Progesterone.Approved, Vet Approved
PromazineMirabegron may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Mirabegron can be increased when it is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be increased when it is combined with Mirabegron.Approved
PropanthelineThe risk or severity of adverse effects can be increased when Propantheline is combined with Mirabegron.Approved
PropiverineThe risk or severity of adverse effects can be increased when Propiverine is combined with Mirabegron.Investigational
PropofolThe metabolism of Propofol can be decreased when combined with Mirabegron.Approved, Investigational, Vet Approved
PropranololThe serum concentration of Mirabegron can be increased when it is combined with Propranolol.Approved, Investigational
ProtriptylineThe serum concentration of Mirabegron can be increased when it is combined with Protriptyline.Approved
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Mirabegron.Approved
QuercetinThe serum concentration of Mirabegron can be increased when it is combined with Quercetin.Experimental
QuetiapineMirabegron may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Mirabegron can be increased when it is combined with Quinacrine.Approved
QuinidineThe risk or severity of adverse effects can be increased when Quinidine is combined with Mirabegron.Approved
QuinineMirabegron may increase the QTc-prolonging activities of Quinine.Approved
RanitidineThe serum concentration of Mirabegron can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Mirabegron can be increased when it is combined with Ranolazine.Approved, Investigational
ReboxetineThe serum concentration of Mirabegron can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibThe serum concentration of Mirabegron can be increased when it is combined with Regorafenib.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Mirabegron.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Mirabegron.Investigational
ReserpineThe serum concentration of Mirabegron can be decreased when it is combined with Reserpine.Approved
RifabutinThe metabolism of Mirabegron can be increased when combined with Rifabutin.Approved
RifampicinThe serum concentration of Mirabegron can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Mirabegron can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Mirabegron can be increased when it is combined with Rilpivirine.Approved
RisperidoneThe metabolism of Risperidone can be decreased when combined with Mirabegron.Approved, Investigational
RitonavirThe metabolism of Mirabegron can be decreased when combined with Ritonavir.Approved, Investigational
RolapitantThe serum concentration of Mirabegron can be increased when it is combined with Rolapitant.Approved
RopiniroleThe metabolism of Mirabegron can be decreased when combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Mirabegron.Approved
RotigotineThe metabolism of Rotigotine can be decreased when combined with Mirabegron.Approved
SaquinavirThe metabolism of Mirabegron can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Mirabegron.Approved
Scopolamine butylbromideThe risk or severity of adverse effects can be increased when Scopolamine butylbromide is combined with Mirabegron.Approved
SelegilineThe serum concentration of Mirabegron can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Mirabegron.Approved, Withdrawn
SertralineThe serum concentration of Mirabegron can be increased when it is combined with Sertraline.Approved
SildenafilThe metabolism of Mirabegron can be decreased when combined with Sildenafil.Approved, Investigational
SilodosinSilodosin may decrease the vasoconstricting activities of Mirabegron.Approved
SiltuximabThe serum concentration of Mirabegron can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Mirabegron can be increased when it is combined with Simeprevir.Approved
SimvastatinThe serum concentration of Mirabegron can be increased when it is combined with Simvastatin.Approved
SirolimusThe serum concentration of Mirabegron can be decreased when it is combined with Sirolimus.Approved, Investigational
SolifenacinThe risk or severity of adverse effects can be increased when Mirabegron is combined with Solifenacin.Approved
SorafenibThe serum concentration of Mirabegron can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolMirabegron may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Mirabegron.Experimental
SpironolactoneSpironolactone may decrease the vasoconstricting activities of Mirabegron.Approved
St. John's WortThe serum concentration of Mirabegron can be decreased when it is combined with St. John's Wort.Nutraceutical
StaurosporineThe serum concentration of Mirabegron can be increased when it is combined with Staurosporine.Experimental
StiripentolThe serum concentration of Mirabegron can be increased when it is combined with Stiripentol.Approved
StreptozocinThe serum concentration of Mirabegron can be decreased when it is combined with Streptozocin.Approved
SulfinpyrazoneThe serum concentration of Mirabegron can be increased when it is combined with Sulfinpyrazone.Approved
SulfisoxazoleMirabegron may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
SumatriptanThe serum concentration of Mirabegron can be increased when it is combined with Sumatriptan.Approved, Investigational
SunitinibThe serum concentration of Mirabegron can be increased when it is combined with Sunitinib.Approved, Investigational
TacrineThe serum concentration of Mirabegron can be increased when it is combined with Tacrine.Withdrawn
TacrolimusThe serum concentration of Mirabegron can be decreased when it is combined with Tacrolimus.Approved, Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Mirabegron resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Mirabegron.Approved, Investigational
TapentadolThe metabolism of Tapentadol can be decreased when combined with Mirabegron.Approved
Taurocholic AcidThe serum concentration of Mirabegron can be increased when it is combined with Taurocholic Acid.Experimental
TegaserodThe metabolism of Tegaserod can be decreased when combined with Mirabegron.Investigational, Withdrawn
TelaprevirThe metabolism of Mirabegron can be decreased when combined with Telaprevir.Approved
TelavancinMirabegron may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Mirabegron can be decreased when combined with Telithromycin.Approved
TelmisartanThe serum concentration of Mirabegron can be increased when it is combined with Telmisartan.Approved, Investigational
TemsirolimusThe serum concentration of Mirabegron can be increased when it is combined with Temsirolimus.Approved
TerazosinThe serum concentration of Mirabegron can be increased when it is combined with Terazosin.Approved
TerbinafineThe metabolism of Mirabegron can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Mirabegron can be increased when it is combined with Terfenadine.Withdrawn
TesmilifeneThe serum concentration of Mirabegron can be decreased when it is combined with Tesmilifene.Investigational
TestosteroneThe serum concentration of Mirabegron can be increased when it is combined with Testosterone.Approved, Investigational
TetrabenazineMirabegron may increase the QTc-prolonging activities of Tetrabenazine.Approved
TheophyllineThe metabolism of Theophylline can be decreased when combined with Mirabegron.Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Mirabegron.Approved
TicagrelorThe serum concentration of Mirabegron can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe metabolism of Mirabegron can be decreased when combined with Ticlopidine.Approved
TimololThe metabolism of Timolol can be decreased when combined with Mirabegron.Approved
TiotropiumThe risk or severity of adverse effects can be increased when Tiotropium is combined with Mirabegron.Approved
TipranavirThe metabolism of Mirabegron can be decreased when combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Mirabegron can be decreased when it is combined with Tocilizumab.Approved
TolterodineThe risk or severity of adverse effects can be increased when Tolterodine is combined with Mirabegron.Approved, Investigational
TolvaptanThe serum concentration of Mirabegron can be increased when it is combined with Tolvaptan.Approved
ToremifeneMirabegron may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Mirabegron.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Mirabegron.Approved, Investigational
TranylcypromineThe metabolism of Mirabegron can be decreased when combined with Tranylcypromine.Approved
TrazodoneThe serum concentration of Mirabegron can be decreased when it is combined with Trazodone.Approved, Investigational
TrifluoperazineThe serum concentration of Mirabegron can be increased when it is combined with Trifluoperazine.Approved
TriflupromazineThe serum concentration of Mirabegron can be increased when it is combined with Triflupromazine.Approved, Vet Approved
TrihexyphenidylThe risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Mirabegron.Approved
TrimazosinTrimazosin may decrease the vasoconstricting activities of Mirabegron.Experimental
TrimethaphanThe risk or severity of adverse effects can be increased when Trimethaphan is combined with Mirabegron.Approved
TrimethoprimThe serum concentration of Mirabegron can be decreased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineThe serum concentration of Mirabegron can be increased when it is combined with Trimipramine.Approved
TroleandomycinThe serum concentration of Mirabegron can be increased when it is combined with Troleandomycin.Approved
TropicamideThe risk or severity of adverse effects can be increased when Tropicamide is combined with Mirabegron.Approved
TrospiumThe risk or severity of adverse effects can be increased when Trospium is combined with Mirabegron.Approved
TubocurarineThe risk or severity of adverse effects can be increased when Tubocurarine is combined with Mirabegron.Approved
UmeclidiniumThe risk or severity of adverse effects can be increased when Umeclidinium is combined with Mirabegron.Approved
VandetanibMirabegron may increase the QTc-prolonging activities of Vandetanib.Approved
VecuroniumThe risk or severity of adverse effects can be increased when Vecuronium is combined with Mirabegron.Approved
VemurafenibMirabegron may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the tachycardic activities of Mirabegron.Approved
VerapamilThe metabolism of Mirabegron can be decreased when combined with Verapamil.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Mirabegron.Approved
VinblastineThe serum concentration of Mirabegron can be decreased when it is combined with Vinblastine.Approved
VincristineThe serum concentration of Mirabegron can be decreased when it is combined with Vincristine.Approved, Investigational
VinorelbineThe serum concentration of Mirabegron can be increased when it is combined with Vinorelbine.Approved, Investigational
VoriconazoleThe metabolism of Mirabegron can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Mirabegron.Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Mirabegron.Approved, Vet Approved
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Mirabegron.Approved
ZimelidineThe serum concentration of Mirabegron can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneMirabegron may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Mirabegron.Approved
ZuclopenthixolMirabegron may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • When taken with meals, levels of mirabegron decreased. Furthermore, the magnitude of this effect was greater if taken with a low fat meal, rather than a high fat meal. Despite these findings, dose adjustment is not required.
References
Synthesis ReferenceNot Available
General References
  1. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899 ]
External Links
ATC CodesG04BD12
AHFS Codes
  • 86:12
PDB EntriesNot Available
FDA labelDownload (510 KB)
MSDSDownload (481 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9398
Blood Brain Barrier+0.8115
Caco-2 permeable-0.6462
P-glycoprotein substrateSubstrate0.5567
P-glycoprotein inhibitor INon-inhibitor0.8492
P-glycoprotein inhibitor IINon-inhibitor0.8487
Renal organic cation transporterNon-inhibitor0.7223
CYP450 2C9 substrateNon-substrate0.7656
CYP450 2D6 substrateNon-substrate0.7786
CYP450 3A4 substrateNon-substrate0.641
CYP450 1A2 substrateNon-inhibitor0.5904
CYP450 2C9 inhibitorInhibitor0.6156
CYP450 2D6 inhibitorNon-inhibitor0.8873
CYP450 2C19 inhibitorNon-inhibitor0.574
CYP450 3A4 inhibitorInhibitor0.5223
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.5711
Ames testNon AMES toxic0.6422
CarcinogenicityNon-carcinogens0.8972
BiodegradationNot ready biodegradable0.5977
Rat acute toxicity2.4527 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9094
hERG inhibition (predictor II)Inhibitor0.567
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, extended releaseOral25 mg
Tablet, extended releaseOral50 mg
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral50 mg/1
PricesNot Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2305802 No2008-11-182018-10-15Canada
CA2464068 No2007-10-162022-10-29Canada
CA2503570 No2023-11-042011-04-19Canada
US6346532 No1998-10-152018-10-15Us
US6562375 No2000-08-012020-08-01Us
US7342117 No2003-11-042023-11-04Us
US7750029 No2003-12-182023-12-18Us
US7982049 No2003-11-042023-11-04Us
US8835474 No2003-11-042023-11-04Us
USRE44872 No2003-12-182023-12-18Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
water solubilityInsoluble FDA label
Predicted Properties
PropertyValueSource
Water Solubility0.00412 mg/mLALOGPS
logP2.2ALOGPS
logP2.89ChemAxon
logS-5ALOGPS
pKa (Strongest Acidic)13.84ChemAxon
pKa (Strongest Basic)9.62ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count4ChemAxon
Polar Surface Area100.27 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity113.23 m3·mol-1ChemAxon
Polarizability44.2 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylamides. These are organic compounds that contain a carboxamide group that is N-linked to a aryl group. They have the generic structure RC(=O)N(R')H, R = organyl group and R'= aryl group.
KingdomOrganic compounds
Super ClassOrganonitrogen compounds
ClassN-arylamides
Sub ClassNot Available
Direct ParentN-arylamides
Alternative Parents
Substituents
  • N-arylamide
  • Phenethylamine
  • Aralkylamine
  • 2,4-disubstituted 1,3-thiazole
  • Benzenoid
  • Primary aromatic amine
  • Monocyclic benzene moiety
  • Heteroaromatic compound
  • Thiazole
  • Azole
  • Secondary carboxylic acid amide
  • Secondary alcohol
  • Carboxamide group
  • 1,2-aminoalcohol
  • Azacycle
  • Organoheterocyclic compound
  • Secondary amine
  • Secondary aliphatic amine
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Aromatic alcohol
  • Primary amine
  • Organooxygen compound
  • Carbonyl group
  • Amine
  • Alcohol
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Protein homodimerization activity
Specific Function:
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. Beta-3 is involved in the regulation of lipolysis and thermogenesis.
Gene Name:
ADRB3
Uniprot ID:
P13945
Molecular Weight:
43518.615 Da
References
  1. Kashyap M, Tyagi P: The pharmacokinetic evaluation of mirabegron as an overactive bladder therapy option. Expert Opin Drug Metab Toxicol. 2013 May;9(5):617-27. doi: 10.1517/17425255.2013.786700. Epub 2013 Apr 4. [PubMed:23550899 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188 ]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Lee J, Moy S, Meijer J, Krauwinkel W, Sawamoto T, Kerbusch V, Kowalski D, Roy M, Marion A, Takusagawa S, van Gelderen M, Keirns J: Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a beta3-adrenoceptor agonist. Clin Drug Investig. 2013 Jun;33(6):429-40. doi: 10.1007/s40261-013-0084-y. [PubMed:23625188 ]
  2. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Identical protein binding
Specific Function:
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name:
BCHE
Uniprot ID:
P06276
Molecular Weight:
68417.575 Da
References
  1. Takusagawa S, Yajima K, Miyashita A, Uehara S, Iwatsubo T, Usui T: Identification of human cytochrome P450 isoforms and esterases involved in the metabolism of mirabegron, a potent and selective beta3-adrenoceptor agonist. Xenobiotica. 2012 Oct;42(10):957-67. doi: 10.3109/00498254.2012.675095. Epub 2012 Apr 18. [PubMed:22509825 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Molecular Weight:
69365.94 Da
Kind
Protein
Organism
Human
Pharmacological action
no
Actions
substrate
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Takusagawa S, Ushigome F, Nemoto H, Takahashi Y, Li Q, Kerbusch V, Miyashita A, Iwatsubo T, Usui T: Intestinal absorption mechanism of mirabegron, a potent and selective beta(3)-adrenoceptor agonist: involvement of human efflux and/or influx transport systems. Mol Pharm. 2013 May 6;10(5):1783-94. doi: 10.1021/mp300582s. Epub 2013 Apr 24. [PubMed:23560393 ]
Comments
comments powered by Disqus
Drug created on May 30, 2013 23:44 / Updated on December 07, 2016 02:39